SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is surging after the company reported positive topline results from a maintenance study of its obesity drug VK2735, showing most prior weight loss retained on less-frequent dosing and roughly 22% placebo-adjusted weight loss at week 33 with no plateau. Traders are divided: bulls call the data best in class and speculate about big-pharma buyout or partnership interest and a potential short squeeze, while bears point to fading intraday gains as a sell-the-news reaction and warn of possible dilution from an existing shelf registration.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is drawing attention after founder Patrick Soon-Shiong teased a push into blockchain-based tokenized stock trading at his Nant platform, leading traders to speculate that IBRX shares could eventually be tokenized and that on-chain settlement could curtail naked shorting and pressure a heavily shorted float. The community is split between bulls framing the tease as a potential squeeze catalyst and skeptics dismissing it as unconfirmed hype, while others also speculate about a possible Anktiva approval in Turkey based on Soon-Shiong's meeting with its president.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is in focus after QNX and Vector Informatik announced the first design win for their jointly developed Alloy Kore vehicle operating system with Coretura, the software-defined vehicle platform founded by Daimler Truck and Volvo Group, which the companies billed as the largest design win in QNX history and a nine-figure addition to the QNX royalty backlog heading into upcoming quarterly results. Reaction is split: bulls celebrate the deal as long-awaited commercial validation and attribute the stock's muted follow-through to manipulation or short pressure, while skeptics counter that Alloy Kore revenue is years from materializing and view the weak price action as a sell-the-news setup ahead of earnings.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is drawing heavy attention as the stock slides back toward the $350 level amid a broad Mag 7 selloff and renewed pressure on AI/hyperscaler names, with rising 10-year yields and Fed rate-hike jitters cited by traders as key macro drivers. The community is sharply split, with many calling the dip a buying opportunity ahead of anticipated Gemini releases and analyst target hikes, while others argue the stock is overvalued and the AI trade is at risk.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is drawing heavy discussion after settling antitrust suits with a coalition of state attorneys general and the Writers Guild, clearing a key legal obstacle to its Warner Bros. Discovery acquisition, with management telling staff the deal is tentatively set to close in about two weeks. Community reaction is split: bullish traders cite deal completion, streaming synergies, and potential warrants, while frustrated holders point to the stock's weak reaction to the settlement news, debating whether it reflects sell-the-news dynamics, merger-related debt concerns, or alleged short-seller manipulation.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is drawing heavy discussion as its shares lag a broader mega-cap tech rally, with traders debating the cause  pointing to reports that Gemini AI agents breached real company systems during a cybersecurity test, speculation that AI tools could disrupt its advertising business, and calls from rival AI labs to slow frontier-model development. Bulls argue a development slowdown would ease hyperscaler capex pressure, while others highlight YouTube's record TV-viewership share coming at Netflix's expense following analyst downgrades.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Traders are reacting to the announced U.S.DenmarkGreenland security agreement, which puts CRML's Tanbreez rare-earth project in Greenland back in focus, though the stock is fading after an initial surge and some see it as a sell-the-news event. Sentiment is sharply split: bulls cite the deal's strategic implications, high short interest, and possible U.S. government stake speculation as squeeze fuel, while bears argue the security pact contains no mining provisions and that dilution and pre-revenue status leave the stock overextended.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is drawing heavy retail attention after a filing showed CEO Ryan Cohen purchased more than 1.1 million shares in open-market transactions, his second sizable buy in recent weeks, lifting shares modestly in extended and premarket trading. Retail reaction is largely bullish, with many reading the insider accumulation as a conviction signalsome speculating it is aimed at pushing upcoming warrants into the money or precedes a company buybackwhile skeptics cite the muted price response, allege suppression, or question whether the purchases are warrant-driven maneuvering.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco is trending amid a sharp sell-off that traders largely attribute to Piper Sandler lowering its price target while keeping a Neutral rating, citing softer sector multiples on fears of peaking growth even as hardware demand outpaces supply. The community is divided between dip-buyers calling the drop an overreaction given Cisco's strong AI networking demand, and frustrated holders selling out or blaming market-maker manipulation, with several arguing the reaction is excessive since the analyst rating itself was unchanged.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is trending on a sharp share-price drop that many traders say came without any accompanying company news, fueling debate over whether it is sell-the-news profit-taking following the strong run-up into the company's investor day or an algorithmic reaction to the posted investor day presentation. Some traders are treating the decline as a buying opportunity at technical support levels, while others see it as a routine pullback after an extended rally.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$IBRX Why This Is New &amp; Significant

- NCCN Guidelines v1.2026 (latest version) now officially recommends ANKTIVA (nogapendekin alfa inbakicept-pmln) + BCG as Category 2B for BCG-unresponsive high-risk NMIBC, including Ta/T1 papillary-only cases (not just CIS).

- Category 2B = &quot;useful in certain circumstances&quot; — based on non-randomized data/expert opinion, but still part of the official standard oncologists use daily.

- Expansion beyond CIS — papillary-only (Ta/T1) patients were previously in a gray area or limited to trials/chemo/intravesical options. Now ANKTIVA + BCG is explicitly recommended, which means:

  - More doctors will prescribe it (NCCN is the bible for treatment decisions).

  - Insurance coverage/reimbursement improves dramatically 

This is not FDA approval (that&#39;s the sBLA pending), but NCCN updates are often more impactful for real-world adoption than FDA news because they influence practice patterns and payors faster.

Nick

XRPHomie

JALIB

Dan Knaup

Steve Richer

John Morin

zaltenbairt

Steve call

$IBRX HUGE milestone — NCCN v1.2026 adding ANKTIVA + BCG as Category 2B for BCG-unresponsive high-risk NMIBC including Ta/T1 papillary-only (beyond CIS) is a game-changer for bladder cancer patients!

https://x.com/truedat999/status/2033716156943765838?s=48

@blueuefinsashashimi @bullishhbruk HUGE milestone - NCCN v1.2026 adding ANKTIVA + BCG as Category 2B for BCG-unresponsive high-risk NMIBC including Ta/T1 papillary-only (beyond CIS) is a game-changer for bladder cancer patients!This expands ANKTIVA to papillary-only cases -...

Groundhog day on X (formerly Twitter): "@blueuefinsashashimi @bullishhbruk HUGE milestone - NCCN v1.2026 adding ANKTIVA + BCG as Category 2B for BCG-unresponsive high-risk NMIBC including Ta/T1 papillary-only (beyond CIS) is a game-changer for bladder ...

StockTwits for iOS

 Why This Is New & Significant

- NCCN Guidelines v1.2026 (latest version) now officially recommends ANKTIVA (nogapendekin alfa inbakicept-pmln) + BCG as Category 2B for BCG-unresponsive high-risk NMIBC, including Ta/T1 papillary-only cases (not just CIS).

- Category 2B = "useful in certain circumstances" — based on non-randomized data/expert opinion, but still part of the official standard oncologists use daily.

- Expansion beyond CIS — papillary-only (Ta/T1) patients were previously in a gray area or limited to trials/chemo/intravesical options. Now ANKTIVA + BCG is explicitly recommended, which means:

  - More doctors will prescribe it (NCCN is the bible for treatment decisions).

  - Insurance coverage/reimbursement improves dramatically 

This is not FDA approval (that's the sBLA pending), but NCCN updates are often more impactful for real-world adoption than FDA news because they influence practice patterns and payors faster.

https://x.com/truedat999/status/2033722566242930821?s=48

Why This Is New & Significant today- NCCN Guidelines v1.2026 (latest version) now officially recommends ANKTIVA (nogapendekin alfa inbakicept-pmln) + BCG as Category 2B for BCG-unresponsive high-risk NMIBC, including Ta/T1 papillary-only cases (not just CIS).- Category 2B =...

X (Formerly Twitter)

Groundhog day on X (formerly Twitter): "Why This Is New & Significant today- NCCN Guidelines v1.2026 (latest version) now officially recommends ANKTIVA (nogapendekin alfa inbakicept-pmln) + BCG as Category 2B for BCG-unresponsive high-risk NMIBC, inclu...